DENVER--(BUSINESS WIRE)--BioIntelliSense, a continuous health monitoring and clinical intelligence company, today announced publication of peer-reviewed research in the Journal of Clinical Medicine titled, “A Retrospective Observational Study of Continuous Wireless Vital Sign Monitoring via a Medical Grade Wearable Device on Hospitalized Floor Patients.”.

。

This study, which was conducted over 15 months in the medical-surgical units of two U.S. hospitals, highlights the transformative potential of medical-grade wearable monitoring technology and algorithmic-based analytics to enhance patient care. The results demonstrated a reduction in patient length of stay, low alert notification rates reducing alert fatigue, and early clinical intervention when patients experienced deterioration events..

这项研究在美国两家医院的医疗外科进行了15个月，突出了医疗级可穿戴监测技术和基于算法的分析技术在改善患者护理方面的变革潜力。结果表明，患者住院时间缩短，警报通知率低，减少警报疲劳，以及患者发生恶化事件时的早期临床干预。。

The study utilized the BioIntelliSense BioButton, a multi-parameter continuous monitoring device, placed on a patient’s upper left chest upon hospital admission. The BioButton continuously measured core vital signs including heart rate at rest, respiratory rate at rest, skin temperature, and activity levels, collecting up to 1,440 measurements per patient per day.

这项研究利用了BioIntelliSense BioButton，一种多参数连续监测设备，在入院时放置在患者的左上胸部。BioButton连续测量核心生命体征，包括休息时的心率，休息时的呼吸频率，皮肤温度和活动水平，每位患者每天收集多达1440次测量结果。

A total of more than 651,000 patient-hours of vital sign readings were captured over the 15-month period, far exceeding what is possible with today’s manual and episodic spot-check collection methods..

在15个月的时间里，总共捕获了651000多个病人小时的生命体征读数，远远超过了今天的手动和偶发性抽查收集方法所能做到的。。

The continuous data was wirelessly and securely transmitted via a BioHub™ Wi-Fi® enabled gateway to the BioIntelliSense BioCloud™ for analysis which employed algorithmic and rules-based notifications to alert healthcare providers to adverse vital sign trends and early indications of potential patient deterioration, on average 14.8 hours prior to the patient presenting symptomatic changes..

连续数据通过BioHub™Wi-Fi®启用的网关无线安全地传输到BioIntelliSense BioCloud™进行分析，该网关采用算法和基于规则的通知来提醒医疗保健提供者注意不良的生命体征趋势和潜在患者恶化的早期指征，平均在患者出现症状变化之前14.8小时。。

“The study underscores the value of implementing continuous monitoring wearable technology, combined with algorithmic-based data analytics, in general care areas of the hospital to automate vital sign collection and to deliver clinical intelligence for actionable decision making,” said James Mault, MD, CEO and Founder of BioIntelliSense.

BioIntelliSense首席执行官兼创始人詹姆斯·莫特（JamesMault）医学博士说：“这项研究强调了在医院的一般护理领域实施持续监测可穿戴技术的价值，并结合基于算法的数据分析，以自动化生命体征采集并为可行的决策提供临床情报。”。

“The BioButton system's ability to deliver timely and accurate notifications enables earlier detection of clinical deterioration and plays a critical role in proactively managing a patient’s health outcomes.”.

“BioButton系统能够提供及时准确的通知，可以及早发现临床恶化，并在主动管理患者的健康结果方面发挥关键作用。”。

Key findings from the study include:

该研究的主要发现包括：

Reduction in hospital stays: length of stay (LOS) in the first unit monitored by the system showed a decreasing trend from 3.07 days to 2.75 days over 12 months which delivers an economic benefit for hospitals and improved satisfaction for patients.

住院时间减少：系统监测的第一个单位的住院时间（LOS）在12个月内从3.07天下降到2.75天，这为医院带来了经济效益，提高了患者的满意度。

Early detection of clinical deterioration: among incidences of clinical deterioration, 73% (Site 1) and 66% (Site 2) had at least one vital sign notification within 24 hours prior to the event. On average, the first vital sign notification was triggered 14.8 hours prior to a deterioration event which may allow for earlier, proactive clinical interventions..

临床恶化的早期发现：在临床恶化的发生率中，73%（部位1）和66%（部位2）在事件发生前24小时内至少有一次生命体征通知。平均而言，第一次生命体征通知是在恶化事件发生前14.8小时触发的，这可能允许更早，积极的临床干预。。

Reduction in alert fatigue: notification rates were <1 per patient per day (0.97 and 0.65 per patient per day at Site 1 and Site 2, respectively), reducing alert noise and fatigue for bedside staff. 40% of patients did not trigger any notifications for their entire stay.

警报疲劳的减少：通知率每天每名患者少于1（现场1和现场2分别为每名患者每天0.97和0.65），减少了床边工作人员的警报噪音和疲劳。40%的患者在整个住院期间没有引发任何通知。

Accurate vital sign measurements: with the BioButton when compared to manually charted bedside readings in an inpatient setting. Heart rate measurements were highly correlated with a mean difference (clinical bias) of 2 beats per minute. Several patient cases were cited in the study that demonstrate that manually collected respiratory rate is error prone when compared to the accurate and objective continuous measurements captured with the BioButton device.

准确的生命体征测量：与住院患者设置中手动绘制的床边读数相比，使用BioButton。心率测量值与每分钟2次搏动的平均差异（临床偏倚）高度相关。该研究引用了几例患者病例，这些病例表明，与使用BioButton设备捕获的准确和客观的连续测量结果相比，手动采集的呼吸频率容易出错。

High respiratory rate notifications showed the highest sensitivity for deterioration events..

高呼吸频率通知显示对恶化事件的敏感性最高。。

Increase in positive patient outcomes: 114 cases saw new or changed physician’s orders as a result of BioButton notifications. Among the new diagnoses were atrial fibrillation, sepsis, and a medication allergy.

积极的患者结果增加：114例患者因BioButton通知而看到了新的或改变的医嘱。新诊断包括心房颤动，败血症和药物过敏。

All the patients in medical-surgical units enrolled in the study (Site 1 with 119 beds and Site 2 with up to 250 beds) were monitored from a centralized location by a single nurse during weekdays on the day shift. 11,977 patients were monitored as part of the 15-month study.

参加研究的医疗外科单位的所有患者（站点1有119张床位，站点2有250张床位）在白班的工作日由一名护士从集中位置进行监测。作为15个月研究的一部分，监测了11977名患者。

For the latest news and information about BioIntelliSense visit our website at biointellisense.com and follow BioIntelliSense on LinkedIn and X.

有关BioIntelliSense的最新新闻和信息，请访问我们的网站BioIntelliSense.com，并在LinkedIn和X上关注BioIntelliSense。

About BioIntelliSense

关于生物智能感知

BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for virtual care and remote patient monitoring (RPM) from in-hospital to home. Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multiparameter vital signs and physiological biometrics through an effortless user experience.

BioIntelliSense开创了一个持续健康监测和临床智能的新时代，用于从医院到家庭的虚拟护理和远程患者监测（RPM）。其医疗级数据即服务（DaaS）平台通过轻松的用户体验无缝捕获多参数生命体征和生理生物特征。

The FDA-cleared BioButton® multiparameter wearable, BioHub™ gateways, BioMobile™ downloadable applications, BioCloud™ data services and the BioDashboard™ clinical intelligence system creates a comprehensive tech-enhanced solution that makes continuous monitoring reliable and scalable. Through the platform’s AI-driven analytics, clinicians have access to high-resolution patient trending and data-driven insights to deliver better, safer care from in-hospital to home..

FDA批准的BioButton®多参数可穿戴、BioHub™网关、BioMobile™可下载应用程序、BioCloud™数据服务和BioDashboard™临床智能系统创建了一个全面的技术增强解决方案，使连续监测可靠且可扩展。通过该平台的人工智能驱动分析，临床医生可以获得高分辨率的患者趋势和数据驱动的见解，从而从住院到家庭提供更好，更安全的护理。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,” “may,” “can,” “continue,” “potential,” “should” and the negative of these terms or other comparable terminology often identify forward-looking statements.

本新闻稿包含前瞻性声明。前瞻性陈述包括所有非历史事实的陈述。诸如“预期”，“期望”，“打算”，“计划”，“预测”，“相信”，“寻求”，“估计”，“可能”，“会”，“会”，“可能”，“可以”，“继续”，“潜在”，“应该”等词以及这些术语或其他类似术语的否定词通常会识别前瞻性陈述。

These forward-looking statements, including statements regarding the use of proceeds, are subject to a number of risks, uncertainties, and assumptions, including those described under 'Risk Factors' in Ardent Health’s Registration Statement. Except as required by law, Ardent Health has no obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations..

这些前瞻性声明，包括关于收益使用的声明，受到许多风险、不确定性和假设的影响，包括Ardent Health注册声明中“风险因素”所述的风险、不确定性和假设。除法律要求外，Ardent Health没有义务更新任何前瞻性声明，以使这些声明符合实际结果或修订后的预期。。